WJPR Citation New

  All Since 2019
 Citation  7475  4312
 h-index  28  21
 i10-index  197  83

Login

Best Paper Awards

World Journal of Pharmaceutical Research (WJPR) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.
Best Paper Award :
Dr. Dhrubo Jyoti Sen
Download Article: Click Here

Search

Track Your Article

Abstract

PAIN MANAGEMENT IN AMAVATA WITH SPECIFIC REFERENCE TO RHEUMATOID ARTHRITIS- A CASE STUDY

Shaktijit Babar*, Darshana Chaure, Ashish Thatere and Prakash Kabra

Abstract

Rheumatoid Arthritis is a chronic multi-system disease of unknown cause, though the most prominent manifestation of Rheumatoid Arthritis is an inflammatory Arthritis of peripheral joints, usually with symmetrical distribution. Rheumatoid Arthritis is a common disease having peak incidence in 3rd to 4th decade of life. The male female ratio is 1:3. The non-steroidal anti-inflammatory, immune modulators or some time steroids relieve the pain, but patients have to face side effects. As well as by the time disease advances contracture and disability develops. This condition resembles with Amavata in Ayurved. Amavata is derived from word “Ama” and “Vata”. The word Ama is the condition in which various ailments in system create toxic effects. The Ama along with Tridosha occupies Shleshmasthana (particularly Asthisandhi) and results in painful disease named as “Amavata”. Langhan, Svedan, Shodhan and Shaman had been depicted for treating Amavata. A case recorded and was treated in our institute. Results obtained are encouraging which are presented in full paper.

Keywords: Amavata, Vaitaran Basti, Jalokavcharana & Shaman.


[Full Text Article]  [Download Certificate]

Call for Paper

World Journal of Pharmaceutical Research (WJPR)
Read More

Email & SMS Alert

World Journal of Pharmaceutical Research (WJPR)
Read More

Article Statistics

World Journal of Pharmaceutical Research (WJPR)
Read More

Online Submission

World Journal of Pharmaceutical Research (WJPR)
Read More